GNCAQ
GENOCEA BIOSCIENCES INC
stockOTC

genocea is harnessing the power of t cell immunity to develop life-changing vaccines and immunotherapies. while traditional immunotherapy discovery methods have largely used predictive methods to propose t cell targets, or antigens, genocea has successfully developed atlas™, its proprietary technology platform, to identify clinically relevant antigens of t cells based on actual human immune responses. genocea is currently using atlas in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by epstein-barr virus.

GENOCEA BIOSCIENCES INC (OTC:GNCAQ) stock price today is $0.00, and today's volume is 5,013. GNCAQ is up 0.000% today. The 30 day average volume is 4,218. GNCAQ market cap is $59 with 58.78M shares outstanding.